Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the <scp>INBUILD</scp> Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial

Published:2022-05-02 Issue:6 Volume:74 Page:1039-1047
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Matteson Eric L.¹^ORCID,Kelly Clive²,Distler Jörg H. W.³^ORCID,Hoffmann‐Vold Anna‐Maria⁴,Seibold James R.⁵,Mittoo Shikha⁶,Dellaripa Paul F.⁷,Aringer Martin⁸^ORCID,Pope Janet⁹^ORCID,Distler Oliver¹⁰^ORCID,James Alexandra¹¹,Schlenker‐Herceg Rozsa¹²,Stowasser Susanne¹³,Quaresma Manuel¹³,Flaherty Kevin R.¹⁴,

Affiliation:

1. Mayo Clinic College of Medicine and Science Rochester Minnesota

2. Newcastle University Newcastle‐upon‐Tyne UK

3. Friedrich‐Alexander University Erlangen‐Nuremberg Erlangen Germany

4. Oslo University Hospital Oslo Norway

5. Scleroderma Research Consultants LLC Aiken South Carolina

6. University of Toronto Toronto Ontario Canada

7. Brigham and Women's Hospital Boston Massachusetts

8. Technical University of Dresden Dresden Germany

9. University of Western Ontario London Ontario Canada

10. University of Zurich Zurich Switzerland

11. elderbrook solutions GmbH Bietigheim‐Bissingen Germany

12. Boehringer Ingelheim Pharmaceuticals, Inc Ridgefield Connecticut

13. Boehringer Ingelheim International GmbH Ingelheim am Rhein Germany

14. University of Michigan Ann Arbor

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.42075

Reference34 articles.

1. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study

2. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort

3. Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study

4. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study

5. Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients;Seminars in Arthritis and Rheumatism;2024-10

2. Efficacy and safety of pharmacological treatments for autoimmune disease-associated interstitial lung disease: A systematic review and network meta-analysis;Seminars in Arthritis and Rheumatism;2024-10

3. Artificial intelligence-based quantification of pulmonary HRCT (AIqpHRCT) for the evaluation of interstitial lung disease in patients with inflammatory rheumatic diseases;Rheumatology International;2024-09-09

4. Guiding ILD management in systemic autoimmune rheumatic diseases;Nature Reviews Rheumatology;2024-09-04

5. A Systematic Review of the Key Predictors of Progression and Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease;Diagnostics;2024-08-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3